Accelerating Therapies With Curia From Conception to Manufacturing
article
internal
Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigate the journey from molecule conception to clinical trials, including the expertise, experience, and preparedness that a CDMO brings to the table.
- The benefits of partnering with a CDMO for navigating the journey from molecule conception to clinical trials.
- Insights into key considerations like the optimal stage to engage with a CDMO and necessary preparations for successful collaboration.
- Curia and the expertise it brings to the table in biologics and small molecules.
In addition to the article, listen to this podcast with greater insight from Curia’s Director, Process Development Science, Scott Alderucci, who leads the process development group at Curia, a global CDMO offering CDMO expertise for biologics and small molecules.